Investor Presentation

August 2013

Active Present Future Positive

Disclaimer
This presentation and the accompanying slides (the Presentation), which has been prepared by Strides Arcolab Limited (the "Company"), has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendation to buy or sell any securities of the Company, and shall not constitute an offer, solicitation or invitation or recommendation to buy or sell in any jurisdiction in which such offer, solicitation or invitation or recommendation is unlawful. No part, or all, of this Presentation shall form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities of the Company. Nothing in the foregoing shall constitute and/or deem to constitute an offer or an invitation to an offer, to be made to the Indian public or any section thereof through this document, and this document and its contents should not be construed to be a prospectus in India. This document has not been and will not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This Presentation is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this Presentation is being provided by the Company and is subject to change without notice. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This Presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as "expects" and "anticipates" and words of similar import. Any statement in this Presentation that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this Presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the Presentation. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements. You acknowledge that you will be solely responsible for your own assessment of the market, the market position, the business and financial condition of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This Presentation speaks as of 30th June 2013. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date. This Presentation is not being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone and the Internet. Neither this Presentation nor any copy of this Presentation is being, and must not be taken or transmitted into the United States or distributed, directly or indirectly, in the United States. The information presented herein is not an offer for sale within the United States of any equity shares or other securities of the Company. No offering of the Companys securities is being made nor will any offering of the Company's securities be registered under the U.S. Securities Act of 1933, as amended (the Securities Act). Accordingly, unless an exemption from registration under the Securities Act is available, the Companys securities may not be offered, sold, resold, delivered or distributed, directly or indirectly, into the United States. The distribution of this Presentation in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about and observe any such restrictions Local market value (LMV) is provided as a reference for assessing the overall market value for a particular type of pharmaceutical product. It should not be considered as an indicator of Strides sales of any its pharmaceutical products or the expected performance of such products in the future. Extrapolation of performance for a particular product from LMVs for such types of products, is an inappropriate use of LMV data. There can be no assurance that our approved pharmaceutical products will be successfully commercialized, or that our current filings will be approved

Introduction

Company overview

Overview
A leading Indian Pharmaceutical company operating in two major segments: Specialties and Pharma Offers wide range of products covering Orals, Semi Solids and Specialty injectables including Beta-lactams, Cephalosporins, Oncolytics and Penems Has one of the largest Lyophilzation (freeze drying) capacities in the world Amongst the leading manufacturers of Soft Gelatin capsules in the world Partnerships with leading global players like Pfizer, GlaxoSmithKline, Aspen, Novartis, Sandoz, and Teva
FY08

Revenue growth (USD mn)

5 Yr CAGR 26%
427 326 169 172 222

FY09

FY10

FY11

FY12

* Excludes divested Ascent Australia operations

INR/USD rate = 53.59

Geographical presence: 14 manufacturing plants + marketing operations in 75 countries

Marketing presence Plant locations 1. Campos, Brazil 2. Lagos, Nigeria 3. Bangalore, Hosur & Mumbai, India 4. Milan, Italy 5. Warsaw, Poland

Filings & approvals track record (ANDA)

259* filings 110* approvals

74

46 27 33 12 1
2005

2012 Revenues by Geography* ATM, Africa, 10% Austral ROW, 12% asia , 8% 11% North America , 32%

30 22 9

31 27

25 5 3

15 8
2008

1
2006 2007 2009 2010 2011 2012

South America, 15%

2013

Filings

Approvals

Europe, 13%

Amongst highest steriles approvals in the industry

*includes purchased and divested ANDAs

* Excludes Divested Australasia Business

Business overview and structure

Founded in 1990, Headquartered in Bangalore, India 2012 revenue of USD 436Mn and EBITDA of USD 106Mn Listed on the Indian stock market since 2000 Restructured business into Pharma and Specialties in 2009

Pharma and Branded Generics business (non-steriles)

2012 Revenue 2012 EBITDA

Specialties business (steriles)

2012 Revenue 2012 EBITDA

42% USD 181Mn

19% USD 20Mn

58% USD255Mn

81% USD 86Mn

Legacy business of Strides established in 1990 Develops and manufactures immunosuppresants and soft gelatin capsules for regulated markets and antiretrovirals, antituberculosis and anti-malaria drugs for programmes funded by donor agencies such as PEPFAR and Global Fund Commercial platform for the sale of branded and commodity generics, OTC and cosmeceuticals across Australia, Southeast Asia, Africa and India Five global manufacturing plants in India, Italy and Nigeria, including one of the largest capacities in soft gelatin capsules with approvals from the US FDA and other key regulatory authorities

Rebranded in 2010 as Agila to reinforce Strides focus on emerging as a sterile-driven pharmaceutical company Develops and manufactures sterile injectable generics and specialties for its B2B and B2C business across therapeutic areas, including anti-infectives, oncology, antibiotics, steroids, cephalosporins, CNS, gastro intestinal, ophthalmics and peptides Nine global manufacturing facilities in India, Brazil and Poland, including one of the largest steriles capacity in India and amongst the largest lyophilisation capacities globally Entered into a definitive agreement with Mylan for sale of its specialty subsidiary at an aggregate sum of USD 1.6bn in cash & potential consideration of upto USD 250Mn

Strides history and achievements

USD Mn
481 436

329

Founded in 1990 as a finished dosage formulation company focused on Africa

80 33 52 86 99

248 202 142 162

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011 2012*

Combined revenues

Pharma

Specialties

(breakdown only available after 2007)

* Divested Ascent Australasia operation to Watson in Jan 12 for AUD 375Mn

1994-2003 Specialised manufacturing

Commenced manufacturing of steriles, soft gelatin capsules and anti-retroviral, tuberculosis and malaria drugs Bolt-on acquisitions of manufacturing capacity

2004-2008 Front-end acquisitions and R&D pipeline

Acquisition and integration of front-end platforms in Southeast Asia (DHA), Australia (Ascent) and India (Grandix) Acquisition of manufacturing facilities in Poland and Italy Significant investment in building R&D pipeline for regulated markets (Pharma and Steriles)

2008 onwards Regulated markets

Restructured into Pharma and Specialties with increased focus on Steriles business Commercial partnerships with global pharma for regulated and emerging markets Front ending in select geographies of North America, EU, Brazil, India & Asia Monetised significant value creation and strengthened Balance sheet by sale of Australasia business to Watson

We continue to focus on pursuing Niche Value. With strong capabilities and commitment, we strive to deliver a cost-efficient operating model aligning consistent innovation and affordable medical care

Strides Key differentiators

Integrated capabilities spanning entire product development cycle Full services provider from identifying business opportunities to product approval and commercialization

2 Focus on R&D resulting in industry leading

formulation expertise Proven R&D markets capabilities for developed

3 Targeting products with significant demand

Increasingly targets products that are (i) in short supply (ii) near term patent expiries (iii) difficult to manufacture segments Moving towards larger sized molecules

Employs around 350 scientists in its R&D department, delivering average 35 ANDAs annually

8 Diversified portfolio across Specialties and

Pharma offers stability Offers wide range of products covering Orals, Semi Solids and Specialty injectables including Beta-lactams, Cephalosporins, Oncolytics and Penems Broad product portfolio is critical for getting GPO contracts in the US (Strides has a contract for sterile injectables with Premier)

4 Solid track record of filings and approvals

259 ANDA filings (213 in steriles) and 110 Approvals (83 in steriles) Branded generics product registrations: 300+ in Africa

Partnership with Big Pharma Partnerships with pharmaceutical majors such as Pfizer, GSK, Novartis, Teva & Aspen in US, Europe, Australia, LATAM, and South Africa Partnerships with Pfizer and GSK validates Strides niche capabilities in sterile injectables and pharmaceuticals portfolio

Solid track record of regulatory compliance Successful inspections by USFDA/EMEA/PIC over the last few years. Continue to maintain strong track record in all Regulatory inspections.

Significant investments completed in manufacturing facilities Significant investments specialties space completed in

Recently FDA approved facilities will accelerate the developed markets strategy

Specialties Business

Steriles - Snapshot

Key strengths
One of the most competitive steriles franchise globally with 9 manufacturing facilities

Product categories Wide range

High Potency Drugs (Oncology, Peptides and Controlled Substances) Antibiotics Penems & Penicillins Cephalosporins Suspension injections Oncology

FDA injectables ANDA approvals by company 2008 to July2012

Strides Sandoz Hospira Hikma Fresenius Luitpold Mylan
19 19 17 14 4 3 2 1 30 30 27 34 42 73

One of the largest lyophilization (freeze drying) capacities in the world

Full services player with a well diversified portfolio

Minibags Ophthalmics and Peptides to be new domains

Track record of filing average 40 ANDAs annually in the last three years

Packaging formats All major types

Significant investment in manufacturing facilities completed Vials Liquid & Dry Powder Pre filled syringes (PFS) Ampoules Long term customer contracts and joint ventures to provide stable revenue stream Market leading ability to package in lyophilized form Focus on pre filled syringes and lyophilized formats

Bedford Teva ACS Dobfar Amgen B Braun Watson Sanofi

Note: * Includes product approvals with JV partners & ANDAs sold to Pfizer in Dec 2010 Source: Approval data sourced from US FDA

Strategy focused on capturing higher value business and sustainable growth

Initial phase Phase-I (2006 [2005-2007] 2008)

Segment Nos of Filings LMV $bn Avg LMV $mn Segment

Phase-II [2008-2010]
Nos of Filings LMV $bn Avg. LMV $mn

Current Phase [2011 onwards]

Segment Nos of Filings LMV $bn Avg. LMV $mn

Steriles
PRODUCT FILINGS

25 1 26

0.3 0.2 0.5

12 221 -

Steriles Oncology Pens & Penems Ophthalmics Total

46 31 8 85

2.2 2.0 0.3 4.5

47 65 38 -

Steriles Oncology Pens & Penems Ophthalmics Total

79 8 2 13 102

9.3 1.3 0.04 0.9 11.5

118 163 20 69

Oncology Pens & Penems Ophthalmics Total

MFG. CAPABILITIES

Building Global manufacturing capabilities for Steriles , Cephalosporin's & Beta lactams

Consolidation and expansion of Global manufacturing capabilities for Steriles Injectables and Oncology

High value creation domains

Biosimilars Devices and delivery systems Para IV & 505b(2) To emerge as a first wave player for most products going off-patent

Focus on Niche small value opportunistic products with distribution of products through JV model
STRATEGY

Focus on large value Niche Sterile and Oncology products Partnering with Big Pharmas Pfizer, Teva etc with profit sharing arrangement

Strengthening partnership for new products/partners & new Geographies Building front ending business in select geographies of USA, UK, Canada, Asia, Turkey, Indonesia, India, Nordic and Brazil Continuing Licensing opportunities in selected domains

10

Significant FDA Approved capacities

Investments towards additional 561m sterile units capacity completed

Capacity expansion

5.8X
Lyo (Non-Onco)

16.5X
Liquid Vials

2.3X
Other Steriles

USFDA Inspection Status

Plant Sterile Product Division I Penicillin, Bangalore Year 2007, 2009, 2011 2008 Approval Status

422

Approved

Capacit y in million units

Approved

Cephalosporin
232 205 181

2009

Approved

Sterile Product Division -II

103

2011

Approved

Oncology

2011

Approved

58 10

58 11
Liquid Vials Other Steriles

Penems, Brazil Sterile Product Division -Hosur Poland

2012

Approved

Lyo (Incl-Onco)

2011

Approved

FDA approved capacity Year 2010

Current FDA approved capacity

Total Capacity

2012

Approved

Well positioned in the industry where regulatory challenges are high

11

Well Positioned For Regulated Markets Opportunity

Increasing focus on high value products
NUMBER OF ANDA FILINGS (LMV - $16.5 Bn)
80 60 40 20 19 0 2006 Oncology Steriles Patented Matured 19 19 7 2007 7 7 22 2008 3 19 3 19 2009 20 22 3 39 42 21 2010 7 14 3 18 30 2011 7 23 5 25 2012 1 67 19 49 67 5 H1'2013 5 4 1 Oncology Steriles Patented Matured 213* 30 25 20 15 10 5 0 2006 -

NUMBER OF ANDA APPROVALS (LMV- $3.5 Bn)

83*

25 1 2007 1 1 13 2008 13 13 5 16 21 2 H1'2013 2 1 1

2009 5 5

2010 16 1 15

2011 12 13 1 24

2012 15 6 21

CUMULATIVE LMV OF ANDA APPROVALS (US$ BN) 2.7 3.0 3.5

Number of filings & Approvals in other Established and Emerging markets

Filings Steriles Europe 42 29 71 24 195 1 215 201 778 Oncology 41 16 17 22 22 24 1 198 341 22 23 33 16 144 156 115 509 Approvals Steriles Oncology 21 13 1 13 20 19 1 62 150

0.7 0.0
2006

0.0
2007

0.2
2008

0.3
2009 2010 2011 2012 H1'2013

ANZ South Africa Canada Africa

Oncology Steriles Patented Matured 0.0 0.0 0.2 0.23 0.3 0.26 0.7 0.07 0.59

1.9 0.8 0.1 2.6

2.1 0.9 0.1 2.9

2.1 1.4 0.6 2.9

Korea Latin America ROW Total

12

Note: LMV (Local Market value): sales in US$ of equivalent products already being sold in the market, whether patented or generic. LMV is not an indicator of Strides expected sales;

12

Value Creation - Sale of Agila Specialties division

for an aggregate cash sum of US$1,600 Mn and potential additional consideration of up to US$250 Mn

On Thursday, 28 February 2013, Strides Arcolab announced that it has entered into a definitive agreement for the sale of its specialties subsidiary, Agila Specialties Private Limited, and simultaneously its overseas specialties subsidiary Agila Specialties Asia Pte. Limited, Singapore, has entered into a definitive agreement for the sale of its subsidiaries, to Mylan Inc. Aggregate sum of US$1,600 million in cash and potential additional consideration of up to US$250 million subject to the satisfaction of certain conditions by Strides At the base consideration, the transaction values Agila at 18.7x total EBITDA for the year ended 31 December, 2012 The transactions have been independently approved by the respective Board of Directors of Strides, its overseas subsidiary and Mylan Inc. The companies being divested recorded, in the aggregate, revenue of $255 million and EBITDA of $86 million for the year ended 31 December, 2012 Closing of the transactions are conditioned upon Foreign Investment Promotion Board approval, customary antitrust approvals and other closing conditions. The transactions are not subject to financing conditions The transactions do not include Agila Biotech Pharma and Biotech business to be future growth areas for Strides

13

Crystallising Significant Value Created at Agila

Creation of a Global Leader in Generic Injectables

Building knowledge base 1996-2000 Opened first sterile facility Focus on contract manufacturing

Investment in infrastructure 2001-2007 Defocused contract manufacturing Decision to target regulated markets Investment in R&D Joint ventures

Accelerated filings and approvals 2008-2011 Large value niche sterile and oncology products Market-leading track record of filings and approvals US FDA facility approvals Big Pharma partnerships

Growth and profitability 2012-onwards Stable cash flows Amongst the largest generic injectables pipelines Best-in-class manufacturing, R&D and operations infrastructure

Value Crystallisation
Strides Arcolab Limited (As at 27 February, 2013) Enterprise Value Agila Specialties Consideration(1)

US$1,329 million

US$1,600 million
( 1) Excludes potential additional consideration of up to US$250 million.

Source: CapIQ.

14

Proposed Use of Proceeds Post Closing

Following successful closing of the transaction, Strides Arcolab proposes to utilise proceeds towards inter alia:

Retiring debt

Pre-tax distribution of approximately US$700 million to US$800 million to shareholders

Costs related to the satisfaction of contingent conditions

15

Pharma Business

Strides Arcolab The Road Ahead for Pharma Division

Segments Overview and Key Growth Drivers

Agila Biotech marks the foray of Strides Arcolab into the biologics space Agila Biotech Planned investments for setting up a next-generation biologics facility in Johor, Malaysia , and to build a 15,000 sq. ft. state-of-the-art R&D facility in Bangalore

Leading generics platform focused on soft gelatin and immunosuppressants for the US and European markets Pharma Generics Strong R&D capabilities with US FDA approved manufacturing infrastructure Exhaustive pipeline focused on products with high entry barriers to drive growth

Africa Business

Leading sales and marketing platform for branded generic pharmaceuticals and over-the-counter medicines across Central and Sub-Saharan Africa Growth driven by launch of new products, expansion into new markets, and establishing local manufacturing

India Brands

Emerging as a regional player in Southern India in niche branded pharmaceutical products Portfolio of recognised brands in fast growing therapeutic segments

17

Agila Biotech
Biosimilars Unfolding Opportunities

Biologics* market expected to grow at a CAGR of 8%-10% during 2010 to 2025, against 4%6% for total pharmaceutical market

Market Overview

Biologics worth $ 59 Billion to lose patent protection by 2015 Biologics market expected to touch $227 billion by 2015 against $126 billion in 2009 Biosimilars# market expected to touch $13 billion by 2015 6 Biosimilars already approved and commercialized in EU

Agila Foray into Biosim Domain

Acquired 100% controlling stake in Inbiopro-a biotechnology focused company

Immediate access to a pipeline of 8 products, estimated to have global sales of US$ 28 billion, with commercialization expected to begin in 2014 The products include 5 monoclonal antibodies which have use in cancer treatment further strengthening Strides oncology products basket Facilities access to high expression mammalian and microbial platform-based capabilities High yielding cell lines in-licensed and improved upon Definite advantage in the biologics industry, which is characterized by specialized expertise in recombinant DNA technology and manufacturing process development with stringent and well defined regulatory guidelines ,resulting in long gestation periods for product development Executed agreement with Malaysian Bio-Xcell for establishment of customized facility to manufacture Biopharmaceuticals and sterile Injectables in the Bio-XCell ecosystem in Johor, 18 Malaysia. Facility will be built by Bio-XCell to the design requirements of Strides and will be leased out to Strides on a long-term basis with lease rentals applicable from the date of commercialization

Competitive Advantage

Manufacturing Facility

18

Agila Biotech
Future Focus Area and Growth Drivers

Agila Biotech marks the companys foray into the biologics space Biologics represent the fastest growing market segment in Pharma accounting for six out of top ten selling global drugs, with patents on first generation biologics expiring by 2020 Planned investments: Next-generation biologics facility in Johor, Malaysia an advanced end-to-end multi-product facility for the production of recombinant therapeutic proteins and monoclonal antibodies (mAbs) from drug substance to drug product in vials, pre-filled syringes and lyophilised products. Expected to come on-stream by end-2014, with significant capacity already advance booked for partner operations R&D facility in Bangalore capable of handling high-end research activities, catering to an internal pipeline as well as partnering activities Developing an internal pipeline of biosimilars, utilising the latest bacterial and mammalian expression systems

19

Pharma Generics

Pharma Business

Soft gels

Global disease initiative (AIDS/TB/Malaria)

Amongst the leading manufacturers of soft gelatin capsules in the world Supplies oral products to regulated markets

Manufacturing

Globally competitive

Develops and manufactures different orals presentation forms and therapeutic categories

Product development capability

Softgel caps, tablets & capsules and semi solids Strength in Immunosuppressants (2 Approved ANDA commercialized) Among the first generic companies to get FDA Approval for Vancomycin Capsule ( LMV $300Mn)

47 ANDA (24 PEPFAR) filings till date of which 26 (19 PEPFAR) have already been approved Orals plants can support growth with limited Capex requirements going forward

Stable revenue stream

Large number of product filings completed Long term customer contracts to provide stable revenue stream Intellectual property led manufacturing partnership in USA, UK, Australia, New Zealand and South Africa

Manufacturing overview

One of largest softgel capacities in the world with five dedicated lines in Orals Drug facility in Bangalore, India Facility approved by major regulatory authorities such as USFDA, MHRA, MCC, TGA and ANVISA EU approved semi solids facility in Milan, Italy

20

Africa and India Brands

Regional Sales exceeding USD 39Mn

Africa
Leading player manufacturing and marketing volume driven generics and margins driven branded products

India
Emerging as a niche player in branded pharmaceutical products

Description

Manufacturing

2 dedicated facilities: 1 in Lagos, Nigeria and 1 in India West Africa, French Africa & other parts of Africa

Orals plant in Bangalore also used for manufacturing branded generics Grandix has presence in 5 states in South India

Footprint

Branded generics, Commodity generics and OTC products marketed through own sales

Products

team in partnership with local distributors French Africa business is front ended comprising ethically promoted and OTC products

Grandix covers therapeutic areas of diabetes, cardiovascular diseases, neurology and female healthcare

Sales Ownership

USD 27Mn 80% stake (20% invested by Proparco, a French Development Financing Institution for USD 12.5 Mn valuing African operation at USD 60Mn)

USD 12Mn

100% stake

21

Financial Snapshot - Pharma Business

Performance ahead of Guidance
USD Million

2013 Guidance

H113 vs H112 - Actuals Revenue

Consolidated Revenue
84

75

USD 182 Mn

H1'12

H1'13

EBITDA
18

Consolidated EBITDA
USD 36 Mn

10

H1'12

H1'13

22

Group Overview

Strides Global Organization

Strides Arcolab Wholly Owned Subsidiary Wholly Owned Subsidiary

Agila Biotech

Pharma Business

Agila Specialties

5 Global
Manufacturing

India Brands

Africa Brands

Assets

9 Global Manufacturing Assets

Front-end Business

IP led Partnerships

Research & Development

Customer focused business organization with dedicated management team

24

Key Performance Indicators

Robust Performance across
USD Million

Revenue from operations

329 248 76 172 2009 222 2010 108

481 155

Operational EBITDA
436 8 97 74 14 39 11 29 60 20

105 0

427 326

77

105

2011 2012 Divested Ascent Operations

2009 2010 Group Excluding Divested Ascent Operations

2011

2012

Note: CAGR excluding divested Ascent operations

Margins trend
22% 16% 20%

24%

2009

2010 3.00 158 2.50 2.00 1.50

2011

2012 58.80 57.74 58.08 2.69 70.00 60.00 50.00 40.00 30.00 20.00 10.00 -

Profit after tax

EPS
40.05 40.23 0.72

42 20 23

1.00 0.50 2012

0.50

0.49

0.49

25

2009 2010 2011 *Includes Profit on sale of Ascent Australasia operations

2008

2009 2010 Outstanding Shares

2011 EPS

2012

Strengthened Balance Sheet post Ascent transaction

Net Debt/Equity at 0.70 in 2012 vs 1.68 in 2011
USD Million

26

Corporate Governance Eminent Independent Directors

Deepak Vaidya Chairman of the Board Was Country Head of Schroder Capital Partners (Asia) Pte. Ltd.

Governance @ Strides

Six out of Eight Board Members are Independent and Non-Executive Strategic themes across the Group are driven by Global Leadership Committee (GLC) Empowered Business Management team with end to end accountability Integrated Management Review from Operations to External Reporting Annual Report received consecutive recognitions for disclosure and presentation of financials.

M.R Umarji Chairman of the Audit Committee Was Executive Director at RBI. Presently the Chief Legal Advisor to the Indian Banks Association

S Sridhar Was CMD of Central Bank of India, ED & COO of Exim Bank, CMD of National Housing Bank.

P.M. Thampi Was Chairman and Managing Director of BASF India

A.K Nair Was MD of KSIDC. MD of Kerala Chemicals and Proteins Limited

Mukul Sarkar Exim Bank Nominee. General Manager and Group Head, Exim Bank

27

Strides has Delivered High Value Creation to its Shareholders

25

Sale of Agila Strides (market share price in USD) Sensex (indexed to Strides)

20

Sale of Ascent Pharma

15

10

Investment Phase
5

A 700% increase in the Market Cap over 5 years, significantly outpacing the BSE increase of 10% over the same period

0 1-Feb-08

1-Dec-08

1-Oct-09

1-Aug-10

1-Jun-11

1-Apr-12

1-Feb-13

Source: BSE,India.

28

28

Shareholding Pattern

as of 30th June 2013

29

Thank You

Strides Arcolab Limited Strides House, Bilekahalli, Bannerghatta Road Bangalore 560076, India Tel: +91 80 67840738 / 67840290 Fax: +91 80 67840200 Web: www.stridesarco.com